Skip to main content
Toggle navigation
Search
Home
Poster Schedule
Home
Poster Schedule
All Days
Wed, Sep 17
Thu, Sep 18
Fri, Sep 19
Poster Schedule
Type here to filter the list
Thursday, September 18, 2025
(PA-489) Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study
(NSP-01) The Use of a BCMA-directed Bispecific Antibody to Treat Relapsed Myeloma in a Liver Transplant Patient Receiving Continuous T-cell Immunosuppression and Concurrent Hemodialysis
(NSP-02) Expanding Access to Bispecific Antibodies for Multiple Myeloma: A Multidisciplinary Model to Bridge Academic and Community Care
(NSP-03) Establishing Barriers and Enablers to Nurse-enabled, Subcutaneous Therapy Self-administration Programs for Myeloma Patients - Description of an Implementation Science Study Design
(NSP-04) Enhancing Patient Education and Support in Multiple Myeloma: A Toolkit-based Nursing Intervention
(NSP-05) Bispecific Antibody Therapy in Haematology: A National Cancer Nurse Education Needs Assessment in the United Kingdom
(NSP-06) Supportive Care Needs and Interventions Among Hospitalised Patients with Myeloma Bone Disease: A Single-centre Experience
(NSP-07) Energy and Macronutrient Deficits in Multiple Myeloma: The Hidden Burden Across the Disease Spectrum
(NSP-08) A Randomized Controlled Trial of Bone-targeted Exercise for People with Multiple Myeloma: The Myeex-impact Study
(NSP-09) Characterising Critical Disease Burdens: Integration of Primary Care Data and Real-time Patient Monitoring to Transform Multiple Myeloma Care in the UK
(NSP-10) Evaluating a Hybrid Approach to Oncology Pharmacy: A Comparison of Service Delivery Models for Immunomodulatory Drug Management
(NSP-11) Clonal Hematopoiesis in Multiple Myeloma: Current Implications and Future Directions
(NSP-12) Quality Improvement Intervention, the Addition of Lifestyle Medicine Group Sessions in Multiple Myeloma Population
(NSP-13) Strategies for a Successful Transition to Short Infusion Isatuximab for Patients with Multiple Myeloma
(NSP-14) An Examination of Perceived Gaps in Multiple Myeloma Education for Nurses
(NSP-15) Supportive Clinical Care Pathways for Patients Receiving Bispecific Antibody and CAR T-cell Therapy for Multiple Myeloma
(NSP-17) The Power of Partnership: Supporting Patient Adherence to Treatment Through a Unique Collaboration of Healthcare Professional and Patient Organisations
(NSP-18) Describing the Impact on Patients Starting Myeloma Therapy by a Myeloma Care Pharmacist in a Specialized Community Oncology Pharmacy Setting
(NSP-19) Diagnostic Journeys in Myeloma: A Qualitative Exploration of Barriers and Facilitators
(NSP-20) Myeloma Patient Outcome Scale (MyPOS): Cross-cultural Adaptation and Evidence of Validity for Brazilian Population
(PA-002) Safety and Efficacy of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Study
(PA-003) Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: A Center for International Blood & Marrow Transplantation Research (CIBMTR) Study
(PA-034) One-time ex-vivo Conditioning of CAR-T Cells with a Novel Metabolic Modulator
(PA-056) CAC-MM-001: Anti-BCMA CAR-T Therapy Followed by Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
(PA-079) Trial in Progress: QUINTESSENTIAL-2—A Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Refractory to Lenalidomide
(PA-080) Arlocabtagene autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
(PA-083) Talquetamab in Brazil: Initial Experience and Outcomes Within an Expanded Access Program
(PA-088) Analysis of Patients With Prior BCMA-Targeted Therapy and Those Achieving CR in REALiTAL: A Multi-Country Observational Study of Talquetamab in RRMM Outside of Clinical Trials
(PA-091) Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
(PA-095) Efficacy and Safety of CAR-T Therapy in CNS-MM
(PA-098) Excellent Outcomes with BCMA Directed T Cell Redirecting Therapies in t(11,14) Relapsed/ Refractory Multiple Myeloma
(PA-101) Long-Term Follow-Up from MajesTEC-1 China Cohort of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: Efficacy Updates, Infection Profile and Immunoglobulin Usage
(PA-104) Splenomegaly Is Associated with High-tumor Burden, Prolonged Cytopenia and Adverse Outcome After BCMA-directed CAR T-cell Therapy
(PA-108) A Comparison of Chemo-free Strategy with Plerixafor Plus G-CSF versus High-dose Cyclophosphamide Plus G-CSF as First-line PBSC Mobilization in Multiple Myeloma Patients: A Chinese Explorative Study
(PA-109) Changes in Patient-reported Distress and Symptom Burden During Talquetamab Therapy in Multiple Myeloma: A Descriptive Analysis
(PA-111) Assessing Positive Behavioral Change in Myeloma Care: An MMRF Longitudinal Study
(PA-113) Time Constraints and Treatment Decisions: How Time Allowed for Decision Making Affects Patient Experience in Relapsed Refractory Multiple Myeloma
(PA-114) Role of the Combination of 3 T Whole-body MRI and 18F-FDG PET/CT in the Management of Multiple Myeloma and Smoldering Myeloma: The New Era of Imaging
(PA-117) Optimisation of Patient-reported Outcome Measurement (PROMs) for Patients with Haematological Cancer Receiving CAR-T and Bispecific Antibodies: Multi-stakeholder Perspectives
(PA-120) Prognostic of Baseline 18F-FDG PET/CT in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
(PA-123) Optimizing Skeletal Health: A Retrospective Analysis of Bone-modifying Agent Prescription Patterns and Incidence of Skeletal-related Events in Multiple Myeloma
(PA-126) Post-Traumatic Growth, Flourishing, and Spiritual Practice Among Adults with Blood Cancer: A Patient-Reported Wellbeing Cross-Sectional Study
(PA-129) Co-designing an Implementation Strategy for a Nurse and Pharmacist-led Intervention Addressing the Long-term Needs of Patients Living with Multiple Myeloma (MM)
(PA-133) Update of the EORTC Quality of Life Multiple Myeloma module (EORTC QLQ-MY20). Results from the Phase I-II EORTC prospective study
(PA-136) An Effective Lenalidomide Desensitization for Delayed Hypersensitivity-induced Rash in Patients with Multiple Myeloma
(PA-137) Predicting Early Mortality Risk in Newly Diagnosed Multiple Myeloma Patients
(PA-140) Imaging Quality and Detection Ability of Whole-body Low-dose CT for Bone and Extraosseous Lesions in Multiple Myeloma
(PA-143) mQOL, a Text-based Remote Therapeutic Monitoring (RTM) Platform for Symptom (Sx) and Quality of Life (QoL) Tracking in Multiple Myeloma (MM): Interim Results from a Prospective Observational Study
(PA-144) Whole Body Magnetic Resonance Imaging (WBMRI) for Response Evaluation in Patients with Multiple Myeloma
(PA-148) Infectious Complications in Patients with Multiple Myeloma: A Scoping Review
(PA-151) Identification of Extracardiac Organ Involvement in Systemic Light Chain Amyloidosis Using 18f-florbetaben Positron Emission Tomography
(PA-154) Health-Related Quality of Life in Indian Patients with Multiple Myeloma: A Pan-India Digital Survey-Based Assessment
(PA-157) Incidence and Risk Factors of Thromboembolic Events in Chinese Patients with Multiple Myeloma: A Single-Center Retrospective Cohort Study
(PA-160) Dialysis-dependence Is Associated with Poor Prognosis in Multiple Myeloma: A Multicenter Retrospective Cohort Study
(PA-162) Cytokine Dysregulation in Multiple Myeloma: A Comprehensive, Comparative Analysis of Blood and Bone Marrow Profiles
(PA-163) Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Folow-Up
(PA-166) Gene-expression-profiling Plus Integrated Multidisciplinary Approach to Detect New-generation Risk-adapted Prognostic Index in Smoldering Myeloma and Multiple Myeloma (GIMPI): A New Prognostic Score
(PA-170) Whole Genome Sequencing of Cell-free DNA for Assessment of Minimal Residual Disease in High-risk Smoldering Multiple Myeloma
(PA-173) Quantitative CD38 Expression and Clinical Response to Anti-CD38 Therapy in Multiple Myeloma: A Retrospective Cohort Analysis
(PA-176) Comparative Evaluation of Advanced Serum-Based Techniques for the Sensitive Detection of Monoclonal Proteins in Multiple Myeloma – A Pilot Study
(PA-179) Verification and Optimization of VTE Risk Stratification System for Multiple Myeloma in China Based on Review Cohort
(PA-183) Bridging the Gap: Conversion of Siemens N-Latex to Binding Site Freelite for Accurate Multiple Myeloma Diagnosis and Risk Stratification
(PA-187) Peripheral Blood Clonotypic Mass Spectrometry-based MRD Stratification Identifies Patients at Increased Risk of Progression After Quadruplet Therapy in NDMM
(PA-190) 3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression
(PA-193) Absolute Lymphocyte Count (ALC) ≥1,000 Is as a Surrogate of Car‑T Cell Expansion and a Readily Available Biomarker to Predict Outcomes in Relapsed/refractory Multiple Myeloma (RRMM)
(PA-196) Clinical Utility of Quantitative, Mass Spectrometry-based EasyM for MRD Monitoring in Multiple Myeloma: Integration with Established MRD Detection Techniques in a Pan-canadian Real-world Cohort Study
(PA-199) Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma
(PA-200) Performance and Additional Benefits of Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry in M-Protein Detection in Plasma Cell Disorders
(PA-203) Ultra-deep, Cost-efficient Whole-genome Sequencing of Cell Free DNA Recovers Most Bone Marrow Mutations in Newly Diagnosed Multiple Myeloma
(PA-205) CoMMpass Explorer: An Interactive Platform to Explore Clinico-Genomic Data from Newly Diagnosed Multiple Myeloma Patients from the CoMMpass Observational Trial
(PA-206) Comprehensive Characterization of Myeloma Genomes from Bone Marrow and Peripheral Blood Using a Novel Clinical Assay
(PA-209) Single Cell RNA and Whole Genome Sequencing Analysis Reveal Distinct Immune and Genomic Signatures in WM Patients Resistant to Ibrutinib Therapy
(PA-212) Spatial Transcriptomics in Extramedullary Multiple Myeloma Reveals an M2 Macrophage Prominent TME
(PA-215) Defining a Novel Cytokine Combination to Optimize In Vitro Culture Conditions for Primary Multiple Myeloma Patient Cells
(PA-218) Bortezomib, Lenalidomide, and Dexamethasone Reverses the Inferior Prognostic Effect of KRAS Mutation in Patients with Newly-diagnosed Multiple Myeloma
(PA-222) Dissecting B Cell Landscape and Receptor Repertoire in Plasma Cell Neoplasms at Single Cell Resolution
(PA-226) MYC Copy Number Variation Detected by FISH Indicates a Similarly Poor Prognosis to MYC Rearrangement in Newly Diagnosed Multiple Myeloma
(PA-227) Characterizing the Molecular Impact of DIS3 Mutation-Driven Mechanisms in Multiple Myeloma
(PA-230) Exploration of Tumor Immune Gene Expression to Stratify Progression Risk in Newly Diagnosed Multiple Myeloma Patients from CoMMpass with 1q Cytogenetic Abnormality
(PA-233) An Integrated Spatial and Single-cell Multiomics Platform for Translational Research in Multiple Myeloma
(PA-236) Longitudinal Analysis of Clonal Hematopoietic Mutations (CHIP) in Transplant Eligible Multiple Myeloma (MM) Patients: Trends From Pre-Transplant to 1 year.
(PA-239) Onco-miR-148a Expression and Its Function in Multiple Myeloma
(PA-242) Stromal Cell Dysfunction and Chronic Inflammation Characterize the Multiple Myeloma Induced Vertebral Fracture
(PA-245) Targeting Lactate Metabolism in Multiple Myeloma to Enhance CAR-T Cells Antitumor Function
(PA-248) Charting Spatial Heterogeneity in Multiple Myeloma by Using a Minimally Invasive Cell-free DNA Profiling
(PA-250) Systematic Assessment of MYC by Fluorescence in situ Hybridization in Multiple Myeloma Identifies a High-Risk Population Independent of Other Risk Factors
(PA-254) Ancestry-Associated Dysregulation of the Bone Marrow T Cell Compartment in Multiple Myeloma Revealed via scRNA-seq and CyTOF Profiling
(PA-259) High Expression of NSD2 in Non t(4;14) Newly-diagnosed Multiple Myeloma Patients May Mimic t(4;14) Biology
(PA-262) Single-Cell Transcriptomic Profiling Reveals Immune Aging and Tumor Microenvironment Imprinting in Smoldering Multiple Myeloma
(PA-265) Unravelling the Effect of Subclonal Copy Number Variants on Immune Microenvironment and Survival
(PA-268) A Vicious Cycle Between Sensory Nerve Outgrowth and Myeloma Tumor Progression in the Bone Marrow
(PA-269) Combining FISH and CMA Improves the Yield of Detection of 17p Deletion in Myeloma
(PA-272) Dual Roles of IRE1α Inhibition in Reversing Mitochondrial ROS-Induced CD8+ T Cell Senescence and Exerting Direct Anti-Tumor Effects in Multiple Myeloma
(PA-274) Retrospective Analysis of Molecular Profile of Plasma Cell Myeloma at Diagnosis
(PA-275) Genomic Profiling of Multiple Myeloma via Optical Genome Mapping: An Exploratory Analysis of Response and Progression in Newly Diagnosed and Relapsed Disease
(PA-278) NAMPT in Myeloma-Associated Macrophages Drives Drug Resistance through Mitochondrial Metabolic Reprogramming and Immune Evasion via the SIRT1/STAT3/SPP1 Axis
(PA-281) LILRB4 Drives Daratumumab Resistance in Multiple Myeloma via STAT3/PIM1 Activation and Lipid Metabolic Reprogramming of the Immune Microenvironment
(PA-283) Fueling the Fighters: Cytokine-Driven Optimization of Allogeneic NK Cells for Multiple Myeloma Immunotherapy
(PA-284) Quadruplet Therapy and ASCT in Multiple Myeloma: Does It Increase Toxicity?
(PA-289) Enhanced Expression of TAGLN2 Predicts Negative Prognosis in Multiple Myeloma
(PA-292) Development of Novel CREB1-PROTACs for Enhanced Targeting of CREB1 in Multiple Myeloma
(PA-296) Treatment Patterns and Outcomes in the Second and Third Lines and After Triple-class Exposure: Subanalysis of the Latin American Multiple Myeloma Registry Study (MYLACRE)
(PA-299) A35, a Novel Small Molecule Kinase Inhibitor, Shows High Efficacy in Multiple Myeloma and Overcomes Imids Resistance
(PA-302) Role and Mechanism of Pim-2 Kinase Inhibitors-induced Immunogenic Cell Death in Multiple Myeloma
(PA-306) Mezigdomide (MEZI) in Novel Targeted Combinations for Relapsed/refractory Multiple Myeloma (RRMM): Updated Results from the Phase 1/2 CA057-003 Trial
(PA-310) HUWE1 Inhibition Impacts MYC Expression Leading to Increased DNA Damage in Combination with Bortezomib
(PA-313) Novel Therapeutic Targets Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) Are Expressed on Malignant Plasma Cells from Patients with Plasma Cell Dyscrasias but Not on Normal Plasma Cells
(PA-318) Precision Medicine in a Patient with Multiple Myeloma Presenting with t(2;11) and CCND1 Overexpression
(PA-321) Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study
(PA-322) eMMpower: A Longitudinal Multi-Center Chart Review Consortium for Multiple Myeloma (MM)
(PA-327) Carfilzomib, Pomalidomide, Dexamethasone±daratumumab Delivers Survival Benefit Regardless of Cytogenetic Risk in Early Relapsed Myeloma Patients：a Multi-center, Prospective Real World Study in China
(PA-330) Prognostic Determinants of Overall Survival in POEMS Syndrome: A 7-Year Single-Center Retrospective Analysis
(PA-332) Clinical Study on the Efficacy and Safety of Aponermin Combined with Dexamethasone-Based Regimen in Multidrug-Resistant Multiple Myeloma
(PA-333) Improved Survival in Multiple Myeloma Following Prior Detection of Precursor Conditions: A Nationwide Real-world Study
(PA-336) Effect of Metformin on Progression-Free Survival in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Phase II Interventional Study in Brazil.
(PA-339) BTK Inhibitors and Bendamustine-Rituximab Demonstrate High Efficacy in Secretory Non-IgM Lymphoplasmacytic Lymphoma
(PA-342) Safety and Efficacy of Elranatamab in Patients with Daratumumab Relapsed And/or Refractory Immunoglobulin Light Chain Amyloidosis
(PA-345) The Evaluation of Circulating Tumor Cells as a Prognostic Biomarker in Newly Diagnosed Light Chain (AL) Amyloidosis
(PA-346) Efficacy and Safety of Frontline Alternating Bortezomib-based Regimens Plus Daratumumab in Primary Plasma Cell Leukemia: Interim Results of Eumeleia Phase 2 Trial by the Greek Myeloma Study Group
(PA-349) EXENT QIP-MS Detection of Stable Monoclonal Light Chain Glycosylation Enables Risk-stratified MGUS Monitoring
(PA-352) The Study of Serum VEGF Expression in Different Types of Plasma Cell Diseases
(PA-356) Light-Chain Smoldering Multiple Myeloma: Natural History and Risk Stratification Based on the iStopMM Definition
(PA-360) The Significance of a MGUS Tumor Board: Updates After Three Years of Success
(PA-363) The Impact of HER2-Directed Treatment on Monoclonal Protein (M-Protein) Levels in Patients with Concomitant Breast Cancer and Plasma Cell Disorders: A Case Series
(PA-366) CALM: A Deep Learning Time Series Model for Predicting Progression from Smoldering Multiple Myeloma Using Clinical Data
(PA-371) Integrative Clinical, Transcriptomic, and Immunohistochemical Characterization of Light Chain Amyloidosis in Bone Marrow and Cardiac Tissue
(PA-375) Real-world Outcomes of SLiM-only Multiple Myeloma: Korean Multicenter Retrospective Analysis
(PA-377) Efficacy and Safety of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma Patients: A Single-center Real-world Study in China
(PA-378) Steady-state Hematopoietic Cell Mobilization for Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab-based Induction Therapy versus Imid-based Induction Therapy: A Real- world Experience
(PA-384) Impact of CD34+ Cell Infusion Dose on Immune Reconstitution and Survival in Multiple Myeloma After Autologous Stem Cell Transplantation
(PA-387) Importance of Re-induction in Patients with Transplant Eligible Multiple Myeloma Refractory to Frontline Therapy
(PA-390) Validation of a Simplified Prognostic Score for Transplant-Ineligible Multiple Myeloma Patients in a Portuguese Cohort: A Real-World Analysis Based on the Greek Myeloma Study Group Model - MEPS
(PA-393) Propensity Score–Weighted Comparison of Daratumumab-Rd versus Daratumumab-VMP, Rd, and VMP in High-Risk Multiple Myeloma: Insights from the MAIA and ALCYONE Trials
(PA-396) Patient Characteristics, Healthcare Utilization and Costs in Multiple Myeloma by Treatment Class Exposure – A German Claims Data Study
(PA-399) Survival Outcomes and Safety of High-dose Melphalan with Autologous Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study
(PA-403) Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia & New Zealand Myeloma and Related Diseases Registry (MRDR).
(PA-405) Nuanced Treatment Decision for Newly Diagnosed Multiple Myeloma Patients Between 65-75 Years Old
(PA-408) Long-term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in the Era of Quadruplets
(PA-409) Real-World Experience with Daratumumab Maintenance After ASCT in Newly Diagnosed Multiple Myeloma (NDMM): Preliminary Data From a Single-Center
(PA-412) Optimization of Post-autologous Hematopoietic Stem Cell Transplant (ASCT) Maintenance Therapy in Multiple Myeloma (MM): Analysis of a Single-center's Results over the Last 5 Years
(PA-416) Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 study
(PA-417) Evaluating a Value-Based, Measurable Residual Disease (MRD) - Focused Clinical Pathway in Patients with Newly Diagnosed Multiple Myeloma
(PA-420) Real-World (RW) Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Front-Line Daratumumab (dara) Lenalidomide (len) and Dexamethasone (dex) (DRd)
(PA-423) HIV and Multiple Myeloma: Do Patients Present at a Younger Age? A Perspective From a South African Orthopaedic Oncology Unit.
(PA-426) Geriatric Assessment in Hematology-Guided Selection for Quadruplet Therapy in Transplant-Ineligible Myeloma. A post hoc analysis from GEM2017FIT trial
(PA-429) Effectiveness of Daratumumab plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd as Frontline Treatment for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Chart Review Study
(PA-432) Exploratory Analyses of Progression-free Survival (PFS) with Lenalidomide-bortezomib-dexamethasone (RVd) Alone/RVd+ASCT by Duffy Genotype in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM)
(PA-436) A Network Meta-Analysis of Randomized Clinical Trials Comparing the Efficacy of Daratumumab Versus Isatuximab in the Treatment of Multiple Myeloma
(PA-439) Model-based Assessment of Monthly Isatuximab Dosing Performance in Newly Diagnosed Multiple Myeloma Patients Using IMROZ Phase 3 Data
(PA-440) Infusional Chemotherapy Regimens for Multiple Myeloma: Characterization of Current-day Use at a Single Center
(PA-443) Lenalidomide Duration during Induction Does Not Affect Stem Cell Mobilisation, A Real-World Study with G-CSF and Pre-emptive Plerixafor
(PA-446) DVRD Induction Followed by Autologous Hematopoietic Stem Cell Transplantation for Older Patients with Multiple Myeloma
(PA-450) Survival of Non-transplanted Newly Diagnosed Multiple Myeloma Patients at the National Cancer Institute of Peru
(PA-454) Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Newly Diagnosed Multiple Myeloma: Outcome and Safety Profile from a Multi-center Real-world Experience
(PA-457) Early Identification of Patients with Multiple Myeloma Progressing within a Short-Term following Tandem Transplantation
(PA-460) Efficacy and Safety of Biweekly/Weekly Ixazomib-Dexamethasone Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma: A Multi-center Study
(PA-462) Real-world (RW) Burden of Infection Among Triple-class–exposed (TCE) Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
(PA-463) Poor Outcomes in Extramedullary Multiple Myeloma Persist Despite Novel Therapies
(PA-466) Survival outcomes of KRD vs. IRD as Second-Line Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Study with Propensity Score Matching
(PA-469) Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
(PA-474) Intravenous Immunoglobulin 10% as Primary Versus Secondary Infection Prophylaxis in Adults with Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3-Directed Bispecific Antibody: A Phase 3 Trial
(PA-477) Validation of a Rule-Based Algorithm for Line-of-Therapy Assignment in Multiple Myeloma Using Simulated Data
(PA-479) First-in-Human, Open-Label, Phase 1 Trial Design of SAR446523, a Novel Anti-GPRC5D Antibody-dependent Cellular Cytotoxicity (ADCC)-enhanced Monoclonal Antibody for Multiple Myeloma
(PA-482) Understanding Specific Treatment Sequences in Multiple Myeloma Dependent on the Treatment Received in Second Line: Survey Data from 141 International Clinicians
(PA-485) Real-world Healthcare Resource Utilization and Costs Among Triple-class–exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Patients With and Without Extramedullary Disease in the United States
(PA-490) Real-world (RW) Treatment (Tx) Patterns and Clinical Outcomes in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM) with 2–4 Lines of Treatment: Data from the US Flatiron Database
(PA-493) Real-World Use of Melflufen plus Dexametasone in Relapsed/Refractory Multiple Myeloma: A Retrospective Study from the Valencian Community and the Region of Murcia (Spain)
(PA-494) Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM
(PA-497) Real World Survival Outcomes of Relapsed and Refractory Multiple Myeloma Patients Receiving Second Line Therapy and Beyond in Asia
(PA-500) Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment (Including Dialysis): Results From the Phase I DREAMM-12 Study
(PA-503) Trial in Progress: REALiTEC-2, an International Retrospective Study of Clinical Outcomes in Patients with Relapsed Refractory Multiple Myeloma Treated with Teclistamab in the Real World
(PA-505) Efficacy and Safety of Isatuximab Subcutaneous (SC) Plus Carfilzomib and Dexamethasone (Isa-Kd) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results of the Phase 2 Study IZALCO
(PA-507) Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/refractory Multiple Myeloma (RRMM)
(PA-510) Delayed or Salvage Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
(PA-513) Clinical Features and Management of GPRC5D related AE in Chinese Relapsed/Refractory Multiple Myeloma Patients Treated with Talquetamab: MonumenTAL-1 China cohort experience
(PA-517) BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma
(PA-518) Case Report: BCMA-targeting CAR T-cell Therapy Induces Complete and Durable Remission in Relapsed Extramedullary Plasmablastic Multiple Myeloma
(PA-523) HDAC and CDK Inhibitor Combinations Synergize in Limiting Myeloma
(PA-524) Iberdomide Maintenance after Autologous Hematopoietic Cell Transplant for Patients who Previously Received Lenalidomide Maintenance
(PA-528) Real-World Management of Relapsed/Refractory Multiple Myeloma Following Early Anti-CD38 Exposure
(PA-531) Single-Cell Sequencing Reveals Transcriptional and Metabolic Divergence of Bone-Involved Multiple Myeloma
